Schedule 8 medicines

​Schedule 8 medicines are subject to strict legislative controls due to their high potential for misuse, abuse and dependence. 

1. except when included in schedule 4
2. (including seeds, extracts, resins and the plant, and any part of the plant) when prepared or packed for human therapeutic use, when:
   1. cultivated or produced, or in products manufactured, in accordance with the narcotic drugs act 1967; and/or
   2. for use in products manufactured in accordance with the narcotic drugs act 1967; and/or
   3. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the Therapeutic Goods Act 1989; and/or
   4. in therapeutic goods supplied in accordance with the Therapeutic Goods Act 1989,
      except when:
      1. it is a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
      2. separately specified in schedule 4; or
      3. separately specified in the nabiximols entry in this schedule; or
      4. in hemp seed oil for purposes other than internal human therapeutic use containing 50 mg/kg or less of cannabinoids
3. except when included in schedule 2, 3 or 4
4. except when included in schedule 4
5. except when included in schedule 2, 3 or 4
6. except when included in schedule 3 or 4
7. (delta-9-tetrahydrocannabinol) when prepared and packed for therapeutic use
   
8. in preparations for human therapeutic use for the treatment of post-traumatic stress disorder when:

    

   1. prescribed, or its supply is authorised, by a medical practitioner: 
      1. registered as a specialist psychiatrist under the Health Practitioner Regulation National Law; 
      2. for whom an authority under the TGA Authorised Prescriber Scheme that covers MDMA is in force
9. (botanical extract of cannabis sativa which includes the following cannabinoids: tetrahydrocannabinols, cannabidiol, cannabinol, cannabigerol, cannabichromene, cannabidiolic acid, tetrahydrocannabinolic acids, tetrahydrocannabivarol, and cannabidivarol, where tetrahydrocannabinols and cannabidiol (in approximately equal proportions) comprise not less than 90 per cent of the total cannabinoid content) in a buccal spray for human therapeutic use
10. except the alkaloids noscapine in schedule 2 and papaverine when included in schedule 2 or 4
11. except when included in schedule 4
12. except when included in schedule 2 or 4
    
13.  in preparations for human therapeutic use for the treatment of treatment-resistant depression, when:
     

    1. prescribed, or its supply is authorised, by a medical practitioner: 
       1. registered as a specialist psychiatrist under the Health Practitioner Regulation National Law; and
          
       2. for whom an authority under the TGA Authorised Prescriber Scheme that covers psilocybine is in force
14. for human therapeutic use
15. when extracted from cannabis for human therapeutic use, when:
    1. included in products manufactured in accordance with the narcotic drugs act 1967; and/or
    2. imported as therapeutic goods, or for use in therapeutic goods, for supply, in accordance with the therapeutic goods act 1989; and/or
    3. in therapeutic goods supplied in accordance with the therapeutic goods act 1989,
       except when:
       1. it is in a product to which item 4, 8, 10, 11 or 12 of schedule 5a to the therapeutic goods regulations 1990 applies; or
       2. in hemp seed oil, containing 50 mg/kg or less of tetrahydrocannabinols when labelled with either of the following warning statements:
          1. not for internal use; or
          2. not to be taken; or
       3. in products for purposes other than for internal human use containing 50 mg/kg or less of tetrahydrocannabinols or
       4. separately specified in the nabiximols entry in this schedule

For further information contact the Duty Pharmaceutical Officer during office hours on (02) 9391 9944.